Lasmotinib

N/A

Report date: 2025/05/23 14:38:40
NME

Base Information

Drug NameLasmotinib
Drug Alias NamePHI-101PHI-101-002PHI-101-003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCheckpoint kinase 2 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsCheckpoint kinase 2Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPharos iBio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPharos iBio Co LtdSeoul National University Hospital
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A